amylin , human

Amylin (8-37), human, derived from human Amylin, possesses direct vasodilator effects in isolated mesenteric resistance arteries of rats. Human Amylin is a small pancreatic β-cell hormone that forms aggregates in the absence of insulin and is a key pathological feature of type II diabetes mellitus.

Amylin, amide, human TFA, a 37-amino acid polypeptide, functions as a pancreatic hormone cosecreted with insulin, playing distinct roles in metabolism and glucose homeostasis by regulating blood sugar through inhibiting glucagon secretion, delaying gastric emptying, and promoting satiety [1].

Amylin (8-37) (human) (hIAPP (8-37)) is the 8-37 fragment of human islet amyloid polypeptide (IAPP) and exhibits a duplex folding with a hairpin structure [1].

Amylin (1-37) (human) (hIAPP (1-37)), a peptide hormone located in pancreatic beta-cell secretory granules, is characterized by an amidated C-terminus and a disulfide bond between cysteine residues 2 and 7 [1].

Acetyl-Amylin (8-37) (human) is a specific amylin antagonist [1].

Tyr-α-CGRP is an N-terminal extended tyrosinated analogue of α-calcitonin gene-related peptide . It binds to amylin receptors AMY1 and AMY3 in COS-7 cells expressing the human receptors (IC50s = 141 and 1.86 nM, respectively). Tyr-α-CGRP also binds to and stimulates cAMP accumulation in rat L6 myocytes (IC50 = 4 nM; EC50 = 12 nM). It also binds to rat brain and spleen membrane preparations (IC50s = 0.2 and 0.5 nM, respectively), induces positive chronotropic and inotropic effects in isolated right and left guinea pig atria (EC50s = 282 and 74 nM, respectively), and inhibits the twitch response in rat vas deferens (EC50 = 1.9 nM).

Pramlintide, a polypeptide analog of human amylin, is an antidiabetic agent with antineoplastic properties in colorectal cancer.

Pramlintide TFA, a polypeptide analogue of human amylin and an antidiabetic agent, exhibits antineoplastic properties in colorectal cancer [1].

Amylin (1-37), human acetate (hIAPP (1-37), acetate), a peptide hormone containing 37 amino acids secreted by the pancreas in conjunction with insulin, inhibits glucagon secretion and produces satiety during glucose homeostasis, and is a major component of amyloid deposits in the pancreas of patients with type 2 diabetes.

NF(N-Me)GA(N-Me)IL is a biologically active peptide, representing a modified segment (amino acids 22 to 27) of the human islet amyloid polypeptide (hIAPP) sequence NFGAIL. This modification includes N-methylations at G24 and I26, transforming the amyloidogenic and cytotoxic nature of the original sequence into a non-amyloidogenic and non-cytotoxic variant. Moreover, the peptide maintains the ability to bind with high affinity to full-length hIAPP, effectively inhibiting its fibril formation.

Amylin, amide, human acetate (122384-88-7, free) is a 37-amino acid peptide hormone co-secreted with insulin. It inhibits glucagon secretion and delays gastric emptying, playing a crucial role in metabolism and maintaining glucose homeostasis.

Amylin, amide, human is a 37-amino acid peptide hormone co-secreted with insulin to regulate postprandial glucose levels, reducing glucagon secretion and delays gastric emptying. DAP Amide's tendency to aggregate into amyloid fibrils is associated with pancreatic β-cell damage in type 2 diabetes.

Pramlintide acetate, a polypeptide analogue of human amylin, functions as an antidiabetic agent and exhibits antineoplastic activity in colorectal cancer.

NN1213 (Peptide 21) is a long-acting human amylin peptide analogue that functions as a selective amylin receptor agonist. It has an EC50 of 0.177 nM for hAMY3R and 0.262 nM for rAMY3R. In both rat and dog models, NN1213 significantly reduces appetite and is utilized in anti-obesity research.